nach oben

Erschienen in:

26.11.2018 | Preclinical study

ANXA2 expression in African American triple-negative breast cancer patients

verfasst von: Lee D. Gibbs, Pankaj Chaudhary, Kelsey Mansheim, Richard J. Hare, Rebecca A. Mantsch, Jamboor K. Vishwanatha

Erschienen in: Breast Cancer Research and Treatment | Ausgabe 1/2019

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Our aim was to determine the role of Annexin A2 (AnxA2), which we have previously found to contribute to the aggressiveness of TNBC, with AA TNBC patients and clinical outcome.

Methods

We analyzed TCGA breast cancer database (n = 1098) to observe AnxA2 expression within breast cancer subtypes and is correlation with overall survival. Further, we examined breast tissue specimens (n = 119) through chromogenic in situ hybridization (CISH) and specimen were scored independently by two pathologists in a blinded study.

Results

In our TCGA analysis, high expression of AnxA2 was correlated with poor survival in patients with TNBC. AnxA2 gene expression was not correlated with poor survival in other breast cancer subtypes. AnxA2 average CISH intensity score (CISH score = 0, null expression to 3, high expression) for TNBC was significantly higher in comparison to estrogen receptor and/or progesterone receptor positive, human epidermal growth factor positive, and non-malignant tissues. Furthermore, AnxA2 average score was significantly higher in AA TNBC patients (CISH average score = 2.45 ± 0.3266) in comparison to Caucasian TNBC patients (CISH average score = 1.1 ± 0.4069).

Conclusion

AnxA2 is overexpressed in TNBC, implicating AnxA2 as a contributor to the aggressive biology of TNBC in AA women.

Nur mit Berechtigung zugänglich

American Cancer Society (n.d.) How common is breast cancer? American Cancer Society. N.p. 12 Mar 2017

Jemal A et al (2011) Global cancer statistics. CA Cancer J Clin 61(2):69–90CrossRefPubMed

Schneider B et al (2008) Triple-negative breast cancer: risk factors to potential targets. Clin Cancer Res 14(24):8010–8018CrossRefPubMed

Albain K et al (2009) Racial disparities in cancer survival among randomized clinical trials patients of the Southwest Oncology Group. J Natl Cancer Inst 101:984CrossRefPubMedPubMedCentral

Rakha EA, Chan S (2011) Metastatic triple-negative breast cancer. Clin Oncol 23(9):587–600CrossRef

Bauer KR et al (2007) Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype. Cancer 109(9):1721–1728CrossRefPubMed

Irshad S, Ellis P, Tutt A (2011) Molecular heterogeneity of triple-negative breast cancer and its clinical implications. Curr Opin Oncol 23(6):566–577CrossRefPubMed

Metzger-Filho O et al (2012) Dissecting the heterogeneity of triple-negative breast cancer. J Clin Oncol 30(15):1879–1887CrossRefPubMed

Millis SZ et al (2015) Predictive biomarker profiling of> 6000 breast cancer patients shows heterogeneity in TNBC, with treatment implications. Clin Breast Cancer 15(6):473–481CrossRefPubMed

10.

Bareche Y et al (2018) Unravelling triple-negative breast cancer molecular heterogeneity using an integrative multiomic analysis. Ann Oncol 29:895–902CrossRefPubMedPubMedCentral

11.

de Graauw M et al (2008) Annexin A2 phosphorylation mediates cell scattering and branching morphogenesis via cofilin activation. Mol Cell Biol 28(3):1029–1040CrossRefPubMed

12.

Gerke V, Creutz CE, Moss SE (2005) Annexins: linking Ca2+ signalling to membrane dynamics. Nat Rev Mol Cell Biol 6(6):449–461CrossRefPubMed

13.

Grieve AG, Moss SE, Hayes MJ (2012) Annexin A2 at the interface of actin and membrane dynamics: a focus on its roles in endocytosis and cell polarization. Int J Cell Biol. https://doi.org/10.1155/2012/852430 CrossRefPubMedPubMedCentral

14.

Valapala M, Vishwanatha JK (2011) Lipid raft endocytosis and exosomal transport facilitate extracellular trafficking of annexin A2. J Biol Chem 286(35):30911–30925CrossRefPubMedPubMedCentral

15.

Kpetemey M et al (2015) MIEN1, a novel interactor of Annexin A2, promotes tumor cell migration by enhancing AnxA2 cell surface expression. Mol Cancer 14(1):156CrossRefPubMedPubMedCentral

16.

Chuthapisith S et al (2009) Annexins in human breast cancer: possible predictors of pathological response to neoadjuvant chemotherapy. Eur J Cancer 45(7):1274–1281CrossRefPubMed

17.

Bharadwaj A, Bydoun M, Holloway R, Waisman D (2013) Annexin A2 heterotetramer: structure and function. Int J Mol Sci 14(3):6259–6305CrossRefPubMedPubMedCentral

18.

Lokman NA, Ween MP, Oehler MK, Ricciardelli C (2011) The role of annexin A2 in tumorigenesis and cancer progression. Cancer Microenviron 4(2):199–208CrossRefPubMedPubMedCentral

19.

Jeon YR et al (2013) Identification of annexin II as a novel secretory biomarker for breast cancer. Proteomics 13(21):3145–3156CrossRefPubMed

20.

Sharma MR et al (2006) Angiogenesis-associated protein annexin II in breast cancer: selective expression in invasive breast cancer and contribution to tumor invasion and progression. Exp Mol Pathol 81(2):146–156CrossRefPubMed

21.

Chaudhary P, Thamake SI, Shetty P, Vishwanatha JK (2014) Inhibition of triple-negative and Herceptin-resistant breast cancer cell proliferation and migration by Annexin A2 antibodies. Br J Cancer 111(12):2328–2341CrossRefPubMedPubMedCentral

22.

Wang CY, Lin CF (2014) Annexin A2: its molecular regulation and cellular expression in cancer development. Disease Markers. https://doi.org/10.1155/2014/308976 CrossRefPubMedPubMedCentral

23.

Shetty PK et al (2012) Reciprocal regulation of annexin A2 and EGFR with Her-2 in Her-2 negative and herceptin-resistant breast cancer. PLoS ONE 7(9):e44299CrossRefPubMedPubMedCentral

24.

Cancer Genome Atlas Network (2012) Comprehensive molecular portraits of human breast tumors. Nature 490(7418):61.CrossRef

25.

Gibbs LD, Vishwanatha JK (2018) Prognostic impact of AnxA1 and AnxA2 gene expression in triple-negative breast cancer. Oncotarget 9(2):2697CrossRefPubMed

26.

Zhu Y, Qiu P, Ji Y (2014) TCGA-assembler: open-source software for retrieving and processing TCGA data. Nat Methods 11(6):599CrossRefPubMedPubMedCentral

27.

Madrid MA, Lo RW (2004) Chromogenic in situ hybridization (CISH): a novel alternative in screening archival breast cancer tissue samples for HER-2/neu status. Breast Cancer Res 6(5):R593CrossRefPubMedPubMedCentral

28.

Hudis CA, Gianni L (2011) Triple-negative breast cancer: an unmet medical need. Oncologist 16(Supplement 1):1–11CrossRefPubMed

29.

Mavaddat N et al (2012) Pathology of breast and ovarian cancers among BRCA1 and BRCA2 mutation carriers: results from the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA). Cancer Epidemiol Prev Biomark 21(1):134–147CrossRef

30.

Nanda R, Schumm LP, Cummings S, Fackenthal JD, Sveen L, Ademuyiwa F, Cobleigh M et al (2005) Genetic testing in an ethnically diverse cohort of high-risk women: a comparative analysis of BRCA1 and BRCA2 mutations in American families of European and African ancestry. JAMA 294(15):1925–1933CrossRefPubMed

31.

Chlebowski RT et al (2005) Ethnicity and breast cancer: factors influencing differences in incidence and outcome. J Natl Cancer Inst 97(6):439–448CrossRefPubMed

32.

Kanaan YM et al (2014) Metabolic profile of triple-negative breast cancer in African-American women reveals potential biomarkers of aggressive disease. Cancer Genomics-Proteomics 11(6):279–294PubMed

33.

Sturtz LA et al (2014) Outcome disparities in African American women with triple negative breast cancer: a comparison of epidemiological and molecular factors between African American and Caucasian women with triple negative breast cancer. BMC Cancer 14(1):62CrossRefPubMedPubMedCentral

34.

Dietze EC et al (2015) Triple-negative breast cancer in African-American women: disparities versus biology. Nat Rev Cancer 15(4):248–254CrossRefPubMedPubMedCentral

35.

Sørlie T et al (2001) Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci 98(19):10869–10874CrossRefPubMed

36.

Sørlie T et al (2003) Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci 100(14):8418–8423CrossRefPubMed

37.

Robinson TJW et al (2013) RB1 status in triple negative breast cancer cells dictates response to radiation treatment and selective therapeutic drugs. PLoS ONE 8(11):e78641CrossRefPubMedPubMedCentral

38.

Gordon V, Banerji S (2013) Molecular pathways: PI3K pathway targets in triple-negative breast cancers. Clin Cancer Res 19(14):3738–3744CrossRefPubMed

39.

Witkiewicz AK et al (2012) RB-pathway disruption is associated with improved response to neoadjuvant chemotherapy in breast cancer. Clin Cancer Res 18(18):5110–5122CrossRefPubMedPubMedCentral

40.

Jiang Z et al (2011) RB1 and p53 at the crossroad of EMT and triple-negative breast cancer. Cell Cycle 10(10):1563–1570CrossRefPubMed

41.

Prat A et al (2013) Molecular characterization of basal-like and non-basal-like triple-negative breast cancer. Oncologist 18(2):123–133CrossRefPubMedPubMedCentral

42.

Lindner R et al (2013) Molecular phenotypes in triple negative breast cancer from African American patients suggest targets for therapy. PloS ONE 8(11):e71915CrossRefPubMedPubMedCentral

43.

Maji S, Chaudhary P, Akopova I, Nguyen PM, Hare RJ, Gryczynski I, Vishwanatha JK (2017) Exosomal annexin II promotes angiogenesis and breast cancer metastasis. Mol Cancer Res 15(1):93–105CrossRefPubMed

44.

Spratt DE et al (2016) Racial/ethnic disparities in genomic sequencing. JAMA Oncol 2(8):1070–1074CrossRefPubMedPubMedCentral

Titel: ANXA2 expression in African American triple-negative breast cancer patients
verfasst von: Lee D. Gibbs
Pankaj Chaudhary
Kelsey Mansheim
Richard J. Hare
Rebecca A. Mantsch
Jamboor K. Vishwanatha
Publikationsdatum: 26.11.2018
Verlag: Springer US
Erschienen in: Breast Cancer Research and Treatment / Ausgabe 1/2019
Print ISSN: 0167-6806
Elektronische ISSN: 1573-7217
DOI: https://doi.org/10.1007/s10549-018-5030-5

Neu im Fachgebiet Onkologie

25.04.2024 | Nierenkarzinom | Nachrichten

Springer Medizin

ANXA2 expression in African American triple-negative breast cancer patients

Abstract

Purpose

Methods

Results

Conclusion

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie

Springer Medizin

Abstract

Purpose

Methods

Results

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2019

Identification, clinical-pathological characteristics and treatment outcomes of patients with metastatic breast cancer and somatic human epidermal growth factor receptor 2 (ERBB2) mutations

Milk intake and mammographic density in premenopausal women

Plasma exosomes stimulate breast cancer metastasis through surface interactions and activation of FAK signaling

Trends in use of bilateral prophylactic mastectomy vs high-risk surveillance in unaffected carriers of inherited breast cancer syndromes in the Inherited Cancer Registry (ICARE)

GGNBP2 suppresses triple-negative breast cancer aggressiveness through inhibition of IL-6/STAT3 signaling activation

G-protein-coupled estrogen receptor GPER-1 expression in hormone receptor-positive breast cancer is associated with poor benefit of tamoxifen

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie